Guest host Dr. Neeraj Agarwal, of the University of Utah Huntsman Cancer Institute and the ASCO Daily News editor-in-chief, discusses updated results from the ENZAMET trial and other advances in prostate cancer and highlights key studies in kidney and bladder cancer with Dr. Jeanny Aragon-Ching, of the Inova Schar Cancer Institute.   TRANSCRIPT  Dr. Neeraj Agarwal: Hello! My name is Dr. Neeraj Agarwal. I'm the director of the Genitourinary (GU) Cancer Program and a professor of Medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of ASCO Daily News.  I'm delighted to have Dr. Jeanny Aragon-Ching, who is one of the associate editors at the ASCO Daily News, to discuss key oral abstracts in the genitourinary cancers, which were presented in the recently concluded 2022 ASCO Annual Meeting.  Dr. Aragon-Ching is a medical oncologist and the clinical program director of the Genitourinary Oncology Program at the Inova Schar Cancer Institute in Virginia.   Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcripts at the ASCO.org\podcasts.  Jeanny, it is great to be speaking with you again and to discuss these practice influencing oral abstract sessions.  Dr. Jeanny Aragon-Ching: Thanks, Neeraj. I'm so very happy to be here. So, let's begin with Abstract 5000 and the ANZUP 1603 trial. This is actually the therapy trial lutetium versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), progressing after docetaxel overall survival after a median follow-up of 3 years. Neeraj, what can you tell us about the study?  Dr. Neeraj Agarwal: Of course, Therapy Study is a randomized trial comparing treatment with lutetium PSMA-617 cabazitaxel in mCRPC patients progressing after docetaxel.  Only patients with high PSMA expression and no sites of fluorodeoxyglucose (FDG) positive, and PSMA negative disease were eligible. Previously, the ANZUP investigators showed a significant improvement in the primary endpoint of the study, which was a prostate-specific antigen (PSA) 50% response rate with 66% for those in the lutetium PSMA arm versus 37% on the cabazitaxel arm. So, PSA 50% response was higher in the lutetium therapy arm over cabazitaxel.  Investigators also reported significant results for key secondary endpoints of progression-free survival with the hazard ratio of 0.63 favoring lutetium therapy, which translates into a 37% reduction in the risk of prostate-specific antigen (PSA), pain or radiographic progression and decreased adverse events of grade 3 or 4 side effects for patients in lutetium PSMA therapy compared to cabazitaxel.  So, this was presented in the past. In this update, Drs. Michael Hoffman and Ian Davis report results on this secondary endpoint of overall survival after a median follow-up of 3 years. In addition to reporting on overall survival, the reanalysis of PSA and radiographic progression-free survival continued to significantly favor the lutetium PSMA arm with a 38% reduction in the risk of progression. After a median follow-up of 36 months, the overall survival was similar in those assigned to lutetium PSMA versus cabazitaxel with a restricted mean survival time of 19.1 months for lutetium therapy versus 19.6 months for cabazitaxel therapy, respectively.  No additional safety signals were identified with the longer follow-up. An important point here is that the therapy trial was never powered for overall survival.  Dr. Jeanny Aragon-Ching: So, this is a very important study indeed, Neeraj. So, what do you think is the key takeaway from this trial?  Dr. Neeraj Agarwal: The key takeaway message here is that while the lutetium PSMA is a suitable option for men with PSMA-positive mCRPC progressing after docetaxel. The similar overall survival compared to cabazitaxel indicates cabazitaxel is also a suitable option for those patients with high PSMA expression.  However, while lutetium PSMA-based therapy and ca